Literature DB >> 31634859

HIV 101: fundamentals of antiretroviral therapy.

Michael S Saag1.   

Abstract

Antiretroviral therapy (ART) should be started as soon as possible after HIV diagnosis. Recommended starting ART regimens in patients with any baseline viral load include ictegravir plus tenofovir alafenamide (TAF)/emtricitabine (FTC), dolutegravir (DTG) plus abacavir/lamivudine, DTG plus TAF (or TDF)/FTC, or DTG plus 3TC. Initial laboratory evaluation includes CD4+ cell count, plasma HIV-1 RNA, and testing for HIV reverse transcriptase and protease resistance mutations. ART regimens do not need to be altered for virologic blips due to release of virus from chronically latently infected cells in patients otherwise exhibiting viral suppression. Patients with continuously undetectable viral load on ART pose virtually no risk of transmitting infection through sexual contact. This article is based on a case-based presentation by Michael S. Saag, MD, at the 2018 Clinical Conference at the National Ryan White Conference on HIV Care & Treatment in December 2018 and intended for clinicians who are new to HIV disease management.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31634859      PMCID: PMC6892619     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  8 in total

1.  Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.

Authors:  Paul E Sax; Edwin DeJesus; Gordon Crofoot; Douglas Ward; Paul Benson; Robin Dretler; Anthony Mills; Cynthia Brinson; Julie Peloquin; Xuelian Wei; Kirsten White; Andrew Cheng; Hal Martin; Erin Quirk
Journal:  Lancet HIV       Date:  2017-02-15       Impact factor: 12.767

2.  Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Authors:  Pedro Cahn; Juan Sierra Madero; José Ramón Arribas; Andrea Antinori; Roberto Ortiz; Amanda E Clarke; Chien-Ching Hung; Jürgen K Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Man; Alexander Currie; Mark Underwood; Allan R Tenorio; Keith Pappa; Brian Wynne; Anna Fettiplace; Martin Gartland; Michael Aboud; Kimberly Smith
Journal:  Lancet       Date:  2018-11-09       Impact factor: 79.321

3.  Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.

Authors:  Miguel Goicoechea; Shanshan Liu; Brookie Best; Shelly Sun; Sonia Jain; Carol Kemper; Mallory Witt; Catherine Diamond; Richard Haubrich; Stan Louie
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

4.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

5.  The antagonism of folate receptor by dolutegravir: developmental toxicity reduction by supplemental folic acid.

Authors:  Robert M Cabrera; Jaclyn P Souder; John W Steele; Lythou Yeo; Gabriel Tukeman; Daniel A Gorelick; Richard H Finnell
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

6.  Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Authors:  Andrew Hill; Sophie L Hughes; Dzintars Gotham; Anton L Pozniak
Journal:  J Virus Erad       Date:  2018-04-01

7.  Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.

Authors:  Joel Gallant; Adriano Lazzarin; Anthony Mills; Chloe Orkin; Daniel Podzamczer; Pablo Tebas; Pierre-Marie Girard; Indira Brar; Eric S Daar; David Wohl; Jürgen Rockstroh; Xuelian Wei; Joseph Custodio; Kirsten White; Hal Martin; Andrew Cheng; Erin Quirk
Journal:  Lancet       Date:  2017-08-31       Impact factor: 79.321

8.  Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Authors:  Alison J Rodger; Valentina Cambiano; Tina Bruun; Pietro Vernazza; Simon Collins; Olaf Degen; Giulio Maria Corbelli; Vicente Estrada; Anna Maria Geretti; Apostolos Beloukas; Dorthe Raben; Pep Coll; Andrea Antinori; Nneka Nwokolo; Armin Rieger; Jan M Prins; Anders Blaxhult; Rainer Weber; Arne Van Eeden; Norbert H Brockmeyer; Amanda Clarke; Jorge Del Romero Guerrero; Francois Raffi; Johannes R Bogner; Gilles Wandeler; Jan Gerstoft; Felix Gutiérrez; Kees Brinkman; Maria Kitchen; Lars Ostergaard; Agathe Leon; Matti Ristola; Heiko Jessen; Hans-Jürgen Stellbrink; Andrew N Phillips; Jens Lundgren
Journal:  Lancet       Date:  2019-05-02       Impact factor: 79.321

  8 in total
  1 in total

1.  Evaluating Islatravir Administered Via Microneedle Array Patch for Long-Acting HIV Pre-exposure Prophylaxis Using Physiologically Based Pharmacokinetic Modelling.

Authors:  Hannah Kinvig; Nicolas Cottura; Andrew Lloyd; Collrane Frivold; Jessica Mistilis; Courtney Jarrahian; Marco Siccardi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-09-30       Impact factor: 2.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.